Clinical Trial Results: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating venetoclax plus azacitidine versus standard of care after allogeneic stem cell transplant in AML was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia (AML), Cancer | Phase 3 | Status: TERMINATED | Results posted: 2026-06-04